Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 23413

Original article / research
Table of Contents - Year : 2017 | Month : November | Volume : 11 | Issue : 11 | Page : SC16 - SC20

Paraoxonase 1 Gene Polymorphism (rs662) and Increased Risk of Idiopathic Foetal Growth Restriction SC16-SC20

Nilesh Chandra, Mohit Mehndiratta, Ashok Kumar Tripathi, Kiran Guleria, Basu Dev Banerjee

Dr. Mohit Mehndiratta,
Associate Professor, Department of Biochemistry, University College of Medical Sciences and Guru Teg Bahadur Hospital,
Delhi-110095, India.

Introduction: Idiopathic Foetal Growth Restriction (IFGR) is a major health challenge. One of the proposed mechanisms for IFGR is oxidative stress. Paraoxonase (PON) enzyme protects Low Density Lipoprotein (LDL) from oxidation. Paraoxonase 1 (PON1) gene polymorphism causes a decrease in PON activity.

Aim: The present study aimed at exploring possible association of PON1 gene Q192R (rs662) polymorphism and expression with development of IFGR.

Materials and Methods: A cross-sectional, case-control study was conducted from December 2011 to March 2013. Seventy five unrelated IFGR neonates and their mothers were recruited as cases with controls. PON1 polymorphism was detected by Polymerase Chain Reaction-Restriction Fragment length Polymorphisn (PCR-RFLP). PON1 expression and activity were assessed by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and spectrophotometrically, respectively. The genotypes were compared using one-way ANOVA. True Fold Change (FC) was used to assess change in gene expression. Chi-square test and t-test were used for the comparison of biochemical data in the different groups.

Results: The QR and RR genotype of rs662 in mothers and neonates were found to be associated with increased incidence of IFGR. Decreased PON1 expression and activity was observed in affected mothers.

Conclusion: Incidence of IFGR is higher in foetus and mothers with unfavourable PON1 rs662 polymorphism and may be used to identify pregnancies at greater risk for Foetal Growth Restriction (FGR).